Compare HITI & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HITI | LUCD |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.6M | 190.8M |
| IPO Year | 2021 | 2021 |
| Metric | HITI | LUCD |
|---|---|---|
| Price | $2.48 | $1.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $6.13 | $4.13 |
| AVG Volume (30 Days) | 371.2K | ★ 685.8K |
| Earning Date | 03-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,346,000.00 |
| Revenue This Year | $23.73 | $115.58 |
| Revenue Next Year | $12.80 | $130.54 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 79.00 |
| 52 Week Low | $2.10 | $0.95 |
| 52 Week High | $4.06 | $1.70 |
| Indicator | HITI | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 59.64 | 54.88 |
| Support Level | $2.43 | $1.01 |
| Resistance Level | $2.51 | $1.52 |
| Average True Range (ATR) | 0.08 | 0.08 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 91.06 | 56.82 |
High Tide Inc is a downstream-focused retailer of cannabis products, distributor, and seller of smoking accessories and cannabis lifestyle products. It is a vertically integrated company in the Canadian cannabis market with various brands in its portfolio such as Canna Cabana, Fastendr, Queen of Bud, Grasscity, Daily High Club, and others. The company's reportable operating segments are: Bricks and mortar, which generates maximum revenue, and E-commerce. Geographically, it derives maximum revenue from its business in Canada, followed by the United States of America, and other international markets.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.